Literature DB >> 6391532

Azathioprine metabolism in kidney transplant recipients.

L Lennard, C B Brown, M Fox, J L Maddocks.   

Abstract

Azathioprine metabolite concentrations were studied in 54 kidney transplant recipients. Thirty-seven of these patients were studied over a 6 month period to investigate the intrapatient variation in metabolite concentrations. All patients had stable functioning grafts and normal peripheral white blood cell counts. The metabolites measured were plasma 6-mercaptopurine and red blood cell 6-thioguanine nucleotide. There was no correlation between azathioprine dose and plasma 6-mercaptopurine concentration but there was a significant correlation between dose and red blood cell 6-thioguanine nucleotide concentration (rs = 0.41, P less than 0.005). The individual transplant recipient showed little variation in metabolite concentrations over several months. Using this group as a control we studied metabolite concentrations in patients with kidney transplants who developed leucopenia. Our preliminary findings indicate that elevated red cell 6-thioguanine nucleotide concentrations, above the control range, can be associated with bone marrow depression.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391532      PMCID: PMC1463549          DOI: 10.1111/j.1365-2125.1984.tb02531.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  RELATIONSHIP BETWEEN METABOLIC FATES AND ANTITUMOR ACTIVITIES OF THIOPURINES.

Authors:  G B ELION; S CALLAHAN; R W RUNDLES; G H HITCHINGS
Journal:  Cancer Res       Date:  1963-09       Impact factor: 12.701

Review 2.  BIOCHEMICAL ASPECTS OF MERCAPTOPURINE INHBITION AND RESISTANCE.

Authors:  R W BROCKMAN
Journal:  Cancer Res       Date:  1963-09       Impact factor: 12.701

3.  Leukopenia and azathioprine management in renal homotransplantation.

Authors:  H C Haesslein; J C Pierce; H M Lee; D M Hume
Journal:  Surgery       Date:  1972-04       Impact factor: 3.982

4.  Immunosuppressive therapy. The relation between clinical response and immunologic competence.

Authors:  M A Swanson; R S Schwartz
Journal:  N Engl J Med       Date:  1967-07-27       Impact factor: 91.245

5.  A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine.

Authors:  D M Tidd; A R Paterson
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

6.  Effects of azathioprine on the human mixed lymphocyte reaction (MLR).

Authors:  S A Al-Safi; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

7.  The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism.

Authors:  W N Kelley; F M Rosenbloom; J E Seegmiller
Journal:  J Clin Invest       Date:  1967-09       Impact factor: 14.808

8.  Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia.

Authors:  L Lennard; C A Rees; J S Lilleyman; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

9.  Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients.

Authors:  S N Lin; K Jessup; M Floyd; T P Wang; C T van Buren; R M Caprioli; B D Kahan
Journal:  Transplantation       Date:  1980-04       Impact factor: 4.939

10.  Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma.

Authors:  J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

View more
  12 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Peliosis hepatis induced by 6-thioguanine administration.

Authors:  D Larrey; E Fréneaux; A Berson; G Babany; C Degott; D Valla; D Pessayre; J P Benhamou
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

4.  Correlation of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration in Han Chinese patients treated with azathioprine 25 to 100 mg: A 1-year, single-center, prospective study.

Authors:  Bo Zhang; Xiao-Wei Xu; Xue-Jun Zeng; Da-Kui Li
Journal:  Curr Ther Res Clin Exp       Date:  2006-07

5.  Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice.

Authors:  V Kurowski; H Iven
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population.

Authors:  M Tinel; A Berson; D Pessayre; P Letteron; M P Cattoni; Y Horsmans; D Larrey
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

7.  Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris.

Authors:  L Lennard; C I Harrington; M Wood; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

8.  6-Thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment for systemic connective tissue diseases: a possible index for monitoring treatment.

Authors:  K Schmiegelow; N J Kriegbaum
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

Review 9.  Clinical pharmacokinetics in organ transplant patients.

Authors:  R Venkataramanan; K Habucky; G J Burckart; R J Ptachcinski
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

Review 10.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Authors:  Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.